| Literature DB >> 32524054 |
Marjan Rafiee1, Kramay Patel1,2, David M Groppe1, Danielle M Andrade1,3, Eduard Bercovici1,3, Esther Bui1,3, Peter L Carlen1,2,3,4,5, Aylin Reid1,3, Peter Tai1,3, Donald Weaver1,3,6, Richard Wennberg1,3, Taufik A Valiante1,2,5,7.
Abstract
OBJECTIVE: Epilepsy is one of the most common neurological disorders . Many individuals continue to have seizures despite medical and surgical treatments, suggesting adjunctive management strategies are required. Promising effects of daily listening to Mozart on reducing seizure frequency in individuals with epilepsy have been demonstrated over the last 20 years, but not in a rigorously controlled manner. In this study, we compared the effect on seizure frequency of daily listening to either Mozart K.448 or a spectrally similar, yet non-rhythmic control piece. We hypothesized that there would be no difference in seizure counts when participants listened to Mozart K.448 vs when they listened to the control piece.Entities:
Keywords: adjunctive therapies; epilepsy; music; neuromodulation; seizure reduction
Year: 2020 PMID: 32524054 PMCID: PMC7278546 DOI: 10.1002/epi4.12400
Source DB: PubMed Journal: Epilepsia Open ISSN: 2470-9239
Inclusion and exclusion criteria
| Inclusion criteria |
Individuals with epilepsy who are not satisfied with their current level of seizure control despite the use of various anti‐epileptic drugs (AEDs) Must have experienced at least three seizures during the baseline period, with the minimum number of one out of three seizures occurring within the last 2 months |
| Exclusion criteria |
History of brain resection surgery (ie, epilepsy surgery) involving removal of any brain structure Any changes in an individual's AEDs during the one‐year intervention period Individuals receiving vagus nerve stimulation (VNS), deep brain stimulation (DBS), or following a ketogenic diet at the time of enrollment, or those planning to use such option(s) in the following year Individuals unable to recall their seizures; inability to document seizure occurrences in a diary during the one‐year intervention period, either by themselves or by their main caregiver Individuals unable to understand and speak English Individuals who score below 55% on the pitch perception and hearing impairment online test prior to starting the intervention |
FIGURE 1Participants flow diagram
Participants demographic information
| Study ID | Gender | Age | AED(s) | MRI Findings | Seizure Type |
|---|---|---|---|---|---|
| 01 | F | 75 | AC, LZ | Normal | A |
| 02 | F | 50 | CB | Left polymicrogyria | CP, N |
| 03 | F | 56 | LC, LV | Right mesial temporal sclerosis | CP, GTC |
| 04 | M | 29 | BR, LC, LM, OX | Normal | N |
| 05 | F | 26 | CB, LM, LC, CL | Normal | SP, CP, N |
| 06 | M | 32 | LV, CB, VA, CL | Generalized brain atrophy | CP, GTC |
| 07 | M | 33 | LM | Right temporal encephalocele | CP |
| 08 | M | 28 | PH, LC, LZ | Occipital horn dilatation | CP, GTC |
| 09 | F | 42 | LM, LC | Normal | CP |
| 10 | F | 53 | CB, LV | Normal | CP, GTC |
| 11 | M | 67 | CB, LC, PR | Normal | CP |
| 12 | F | 42 | TO | Multiple bilateral white matter hyperintensities | CP |
| 13 | F | 63 | VA | Normal | CP |
Abbreviations: A, absence; AC, acetazolamide; BR, brivaracetam; CB, carbamazepine; CL, clobazam; CP, complex partial; GTC, generalized tonic‐clonic; LC, lacosamide; LM, lamotrigine; LV, levetiracetam; LZ, lorazepam; N, nocturnal; OX, oxcarbazepine; PH, phenytoin; PR, perampanel; SP, simple partial; TO, topiramate; VA, valproic acid.
Results of Student's t test for paired samples and the related statistical analysis
| Intention to Treat | Per‐Protocol | |||||
|---|---|---|---|---|---|---|
| Period | Period | |||||
| Treatment | Control | Within‐individual differences (Treatment‐Control) | Treatment | Control | Within‐individual differences (Treatment‐Control) | |
| Mozart‐Control | ||||||
| Mean (SD) | 0.6 (0.3) | 1.2 (0.6) | −0.6 [−1.2 to −0.1] | 0.4 (0.2) | 1 (0.4) | −0.5 [−1.0 to −0.1] |
| Sample size | 7 | 7 | 7 | 5 | 5 | |
| Control‐Mozart | ||||||
| Mean (SD) | 0.7 (0.2) | 1.2 (0.1) | −0.4 [−0.7 to −0.2] | 0.7 (0.2) | 1.1 (0.1) | −0.4 [−0.6 to −0.2] |
| Sample size | 6 | 6 | 6 | 6 | 6 | |
| Treatment Effect | ||||||
| Mean (SD) | ‐ | ‐ | −0.5 [−0.7 to −0.3] | ‐ | ‐ | −0.5 [−0.7 to −0.3] |
|
| ‐ | ‐ |
|
| ||
| Sample size | 13 | 13 | 11 | 11 | ||
The mean values correspond to the mean of the normalized total number of seizures in each three months period. The numbers shown for within‐individual differences correspond to the mean [95% CI].
FIGURE 2Estimation graphics to display the effect size under (A) intention to treat (n = 13) and (B) per‐protocol (n = 11) analysis. The blue and red lines connect the paired observations on the seizure counts during the control and treatment periods for individuals in groups A and B, respectively. Horizontally aligned with the mean of the treatment group, the purple curve represents the resampled distribution of the mean differences between the seizure counts during the control and treatment periods or Δ, indicated by the purple circle. The axis origin, indicated by a black horizontal line, by definition represents the mean of the null hypothesis and is equal to zero